Genakumab

SSc-ILD Market Projected to Reach $750 Million by 2034 as Novel Therapies Enter Pipeline

a month ago

• The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market was valued at approximately $750 million in 2022 and is expected to grow significantly through 2034, driven by increasing disease prevalence and emerging therapies. • aTyr Pharma continues enrollment in its Phase 2 EFZO-CONNECT study evaluating efzofitimod for SSc-ILD, with participants receiving either 270mg, 450mg, or placebo administered intravenously over six monthly doses. • Several promising candidates in the pipeline, including PRA023, Belimumab, and Vixarelimab, are poised to reshape the treatment landscape for SSc-ILD, addressing significant unmet needs in this serious pulmonary complication.

Rheumatoid Arthritis Market Set to Reach $34.7 Billion by 2035, Driven by Novel Therapies and Rising Obesity Rates

3 months ago

• The global rheumatoid arthritis market is projected to grow from $28 billion in 2024 to $34.7 billion by 2035, with a CAGR of 1.97%, fueled by advancements in biologics and targeted therapies. • Rising obesity rates, sedentary lifestyles, and urbanization are significantly contributing to increased rheumatoid arthritis prevalence, while also reducing the efficacy of some treatments. • Novel treatment approaches including JAK inhibitors, monoclonal antibodies, and emerging therapies like R-2487 and IMVT-1402 are transforming the treatment landscape with more targeted mechanisms of action.

SSc-ILD Market Projected to Reach $750 Million by 2034 as Novel Therapies Enter Pipeline

Rheumatoid Arthritis Market Set to Reach $34.7 Billion by 2035, Driven by Novel Therapies and Rising Obesity Rates

Drug Development Updates